Antimicrobial Resistance Surveillance Market Size & Share 2024 to 2032

Antimicrobial Resistance Surveillance Market Size

Antimicrobial Resistance Surveillance Market size was valued at USD 5.9 billion in 2023 and is estimated to expand at around 5.8% CAGR from 2024 to 2032. Antimicrobial resistance surveillance refers to the systematic and ongoing monitoring of the prevalence and patterns of antimicrobial resistance (AMR) in various pathogens, including bacteria, viruses, fungi, and parasites. This surveillance is crucial for understanding how resistant these pathogens are to the drugs that are typically used to treat infections they cause.

The rising incidence of antimicrobial resistance has become a significant public health concern globally. For instance, according to the LANCET, antimicrobial resistance contributes to about 7,00,000 deaths annually, and without effective intervention these are projected to cause 10 million deaths by 2050. Thus, as the prevalence of antimicrobial resistance continue to rise, there is a growing demand for effective strategies in managing and addressing this issue, including advanced measures for surveillance, prevention, and appropriate use of antimicrobial agents.
 

Additionally, rising awareness and screening programs, increasing prevalence of infectious diseases, growing infectious disease diagnostics which is estimated to reach USD 40 billion by 2032, and advancements in screening technologies, are among other contributing factors escalating the growth of the market.
 

Antimicrobial Resistance Surveillance Market Trends

The increasing prevalence of infectious diseases is a significant driver for the antimicrobial resistance (AMR) surveillance industry. As, infectious diseases become more prevalent, there is a greater need for effective treatment. This often leads to increased use of antimicrobial drugs, leading to the likelihood of the development of antimicrobial resistance.
 

• For instance, according to the Centers for Disease Control and Prevention, the number of visits to physician offices for infectious and parasitic diseases increased to 10.2 million.
   
• Further, infectious diseases with antimicrobial-resistant strains pose a significant public health threat. They can spread more easily and widely, leading to outbreaks and even pandemics. Thus, surveillance is crucial for detecting these resistant strains early, allowing for timely responses such as targeted interventions and infection control measures.
   
• Moreover, antimicrobial resistance increases the economic burden on healthcare systems. As, treating infections with resistant strains often requires more expensive and complex therapies, and molecular diagnostics. Therefore, surveillance helps in optimizing treatment regimens, reducing unnecessary antibiotic prescriptions, and ultimately saving healthcare costs, thereby augmenting the market growth.
   

Antimicrobial Resistance Surveillance Market Analysis

Based on solution, the market is divided into diagnostic kits, diagnostic systems, diagnostic software, and services. The diagnostic kits segment is poised to surpass USD 4.2 billion by the end of 2032.
 

• Diagnostic kits provide rapid and accurate identification of pathogens and their antimicrobial resistance profiles. This is crucial for timely and targeted treatment, allowing healthcare providers to administer the most effective antibiotics promptly.
   
• Further, these kits are often user-friendly and require minimal training to operate. This makes them accessible in various healthcare settings, including resource-limited areas where sophisticated laboratory equipment may not be available.
   
• Additionally, many diagnostic kits are designed for point-of-care testing, and can be used directly at the patient's bedside or in clinics. Thus, due to the several advantages they are expected to boost the segmental growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the antimicrobial resistance surveillance market is classified into public health surveillance, laboratory surveillance, clinical diagnostics, and other applications. The clinical diagnostics segment held over USD 2.4 billion revenue in 2023.
 

• Clinical diagnostics are directly tied to patient care. With the rise of antimicrobial resistance, it has become crucial to identify resistant pathogens early. Consequently, it can quickly detect the presence of resistant strains and help guide physicians in prescribing appropriate antimicrobial therapy, reducing the risk of treatment failure.
   
• Furthermore, these diagnostic techniques include various tests, such as culture-based methods, molecular assays, and susceptibility testing, which enable the identification of specific pathogens and their resistance patterns to antimicrobial agents.
   
• Moreover, clinical diagnostics are essential for effective surveillance, as it support the efforts to combat antimicrobial resistance, and preserve the efficacy of antimicrobial agents for patient care, thereby escalating the segmental growth.
   

Based on end-use, the antimicrobial resistance surveillance market is segmented into hospitals, clinics, research & academic institutes, and other end-users. The hospitals segment accounted for 45.7% of the market share in 2023.
 

• Hospitals play a crucial role in antimicrobial surveillance as they serve as key sites for monitoring and managing antimicrobial resistance within healthcare settings.
   
• Furthermore, hospitals track changes in resistance patterns over time, allowing for the early detection of emerging threats and the identification of high-risk areas or patient populations.
   
• Moreover, by guiding treatment decisions, implementing stewardship programs, and enhancing infection control measures, hospitals contribute significantly to efforts aimed at combating antimicrobial resistance and safeguarding patient care, and thus, fostering the growth of the market.
   

North America antimicrobial resistance surveillance market size dominated around USD 2.4 billion 2023.
 

• The region is boasted with a sophisticated healthcare infrastructure, significant technological advancements, stringent regulations, and rising incidence of antimicrobial resistance.
   
• For instance, according to the Centers for Disease Control and Prevention (CDC), in 2019, over 2.8 million antimicrobial-resistant infections were reported in the U.S., resulting in more than 35,000 deaths.
   
• Furthermore, there is high awareness among healthcare professionals, and policymakers about the threats posed by antimicrobial resistance. This awareness drives the adoption of surveillance practices to monitor resistance patterns and guide appropriate antimicrobial use.
   

Antimicrobial Resistance Surveillance Market Share

The antimicrobial resistance surveillance industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, Thermo Fisher Scientific, Becton, Dickinson and Company, among others have a notable presence in the market.
 

Antimicrobial Resistance Surveillance Market Companies

Some of the eminent market participants operating in the antimicrobial resistance surveillance industry include:

• Abbott Laboratories
• Accelerate Diagnostics, Inc.
• Becton, Dickinson and Company (BD)
• Biomereiux SA
• Bruker Corporation
• Himedia Laboratories Pvt. Ltd.
• Opgen Inc.
• Danaher Corporation
• Luminex Corporation
• Merck & Co., Inc.
• Thermo Fisher Scientific Inc.
   

Antimicrobial Resistance Surveillance Industry News

• In October 2021, Thermo Fisher Scientific launched the ASTar System, offering rapid antimicrobial susceptibility testing with true MIC results in 6 hours. This innovation improved efficiency and effectiveness in testing processes, leading to better healthcare management and patient care. Thus, it increased the surveillance sector and thereby reach of the company.
   
• In June 2020, OpGen, Inc, announced its strategic collaboration with the New York State Department of Health (“DOH”) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions state wise. This strategy allowed the company to expand its surveillance sector and thus helped to establish as a pioneer in the field.
   

The antimicrobial resistance surveillance market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Solution

• Diagnostic kits
• Diagnostic systems
• Diagnostic software
• Services

Market, By Application

• Public health surveillance
• Laboratory surveillance
• Clinical diagnostics
• Other applications

Market, By End-use

• Hospitals
• Clinics
• Research & academic institutes
• Other end-users

The above information has been provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa